Protocol Ledger

NCT05522660 · Phase III · RECRUITING

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT05522660 sponsored by ETOP IBCSG Partners Foundation in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-30 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05522660
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05522660
Protocol FieldVerified Registry Value
NCT IdentifierNCT05522660
Consolidated Lead SponsorETOP IBCSG Partners Foundation
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2022-11-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05522660
Hospital Research SiteLocationSite Profile
Universitätsspital ZürichZurich, SwitzerlandOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI